Investor · 1 deal
Every published round Cure Kids Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Cure Kids Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Amaroq Therapeutics | 8 Jul 2021 | 1 | 0 |
Fund closes reported for Cure Kids Ventures, as distinct from the investments it has made.
Companies Cure Kids Ventures has backed that another company then bought. An exit for the holding, not a deal Cure Kids Ventures did.
Stories naming Cure Kids Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of eight Australian and New Zealand startups whose late-July funding totals $102 million across space capsules, medical devices, livestock breath analysis, sports analytics and AI crop forecasting.
Weekly roundup of ten Australian and New Zealand startup raises totalling nearly $194 million, topped by Neara's $90 million round at a $1.1 billion valuation, with Splose, Operata, HAMR Energy and Adora also covered.
Medtech firm Kitea Health has wrapped an oversubscribed $13 million round, with Icehouse Ventures leading, to fund planned American human trials of its implanted pressure sensor.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Brandon Capital's site announces it led $14m for Amaroq Therapeutics, an Otago spinout developing RNA-based cancer treatments — the firm's first deal as a government-backed incubator. The piece also recalls Kea Therapeutics' shutdown.
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.
University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio